Tango Therapeutics (TNGX) Operating Leases: 2020-2025
Historic Operating Leases for Tango Therapeutics (TNGX) over the last 3 years, with Sep 2025 value amounting to $31.7 million.
- Tango Therapeutics' Operating Leases fell 8.92% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.7 million, marking a year-over-year decrease of 8.92%. This contributed to the annual value of $34.0 million for FY2024, which is 7.60% down from last year.
- Per Tango Therapeutics' latest filing, its Operating Leases stood at $31.7 million for Q3 2025, which was down 2.50% from $32.5 million recorded in Q2 2025.
- Tango Therapeutics' Operating Leases' 5-year high stood at $39.9 million during Q3 2022, with a 5-year trough of $6.1 million in Q3 2021.
- In the last 3 years, Tango Therapeutics' Operating Leases had a median value of $35.5 million in 2024 and averaged $35.4 million.
- Per our database at Business Quant, Tango Therapeutics' Operating Leases skyrocketed by 556.05% in 2022 and then decreased by 8.92% in 2025.
- Over the past 5 years, Tango Therapeutics' Operating Leases (Quarterly) stood at $6.1 million in 2021, then soared by 556.05% to $39.4 million in 2022, then declined by 6.41% to $36.8 million in 2023, then dropped by 7.60% to $34.0 million in 2024, then dropped by 8.92% to $31.7 million in 2025.
- Its Operating Leases stands at $31.7 million for Q3 2025, versus $32.5 million for Q2 2025 and $34.1 million for Q1 2025.